Management of Hyperglycaemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2018 Oct 6

PMID 30288571

Citations 432

Authors

Melanie J Davies

David A DAlessio

Judith Fradkin

Walter N Kernan

Chantal Mathieu

Geltrude Mingrone

Peter Rossing

Apostolos Tsapas

Deborah J Wexler

John B Buse

Affiliations

Soon will be listed here.

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.

Citing Articles

Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations.

Shah M, Roebuck A, Srinivasan B, Ward J, Squires P, Hills C Front Endocrinol (Lausanne). 2025; 15:1499681.

PMID: 39911238 PMC: 11794822. DOI: 10.3389/fendo.2024.1499681.

Assessing the Nutrient Composition of a Carnivore Diet: A Case Study Model.

Goedeke S, Murphy T, Rush A, Zinn C Nutrients. 2025; 17(1.

PMID: 39796574 PMC: 11722875. DOI: 10.3390/nu17010140.

Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach.

Pfaar O, Peters A, Taille C, Teeling T, Silver J, Chan R Clin Transl Allergy. 2025; 15(1):e70010.

PMID: 39794887 PMC: 11723824. DOI: 10.1002/clt2.70010.

Neuroendocrine tumors and diabetes mellitus: which treatment and which effect.

Mazzilli R, Zamponi V, Mancini C, Giorgini B, Golisano B, Mikovic N Endocrine. 2025; .

PMID: 39752043 DOI: 10.1007/s12020-024-04149-9.

Supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH.

Wang Q, Zhou Y, Ni Y, Wang Z, Lou Y, Yang Z Diabetol Metab Syndr. 2024; 16(1):303.

PMID: 39695722 PMC: 11658388. DOI: 10.1186/s13098-024-01513-7.

References

Sainsbury E, Kizirian N, Partridge S, Gill T, Colagiuri S, Gibson A . Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2018; 139:239-252. DOI: 10.1016/j.diabres.2018.02.026. View

Rosenstock J, Fonseca V, Schinzel S, Dain M, Mullins P, Riddle M . Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. J Diabetes Complications. 2014; 28(5):742-9. PMC: 4802045. DOI: 10.1016/j.jdiacomp.2014.04.003. View

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni A . Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017; 5(11):887-897. DOI: 10.1016/S2213-8587(17)30317-0. View

Cefalu W, Kaul S, Gerstein H, Holman R, Zinman B, Skyler J . Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors' Expert Forum. Diabetes Care. 2017; 41(1):14-31. PMC: 5741160. DOI: 10.2337/dci17-0057. View

Mann J, Orsted D, Brown-Frandsen K, Marso S, Poulter N, Rasmussen S . Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med. 2017; 377(9):839-848. DOI: 10.1056/NEJMoa1616011. View

Rosenstock J, Hollander P, Bhargava A, Ilag L, Pollom R, Zielonka J . Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2.... Diabetes Obes Metab. 2015; 17(8):734-41. DOI: 10.1111/dom.12482. View

Scirica B, Bhatt D, Braunwald E, Steg P, Davidson J, Hirshberg B . Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-26. DOI: 10.1056/NEJMoa1307684. View

Gangji A, Cukierman T, Gerstein H, Goldsmith C, Clase C . A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007; 30(2):389-94. DOI: 10.2337/dc06-1789. View

Storgaard H, Cold F, Gluud L, Vilsboll T, Knop F . Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19(6):906-908. DOI: 10.1111/dom.12885. View

10.

Mahalingam Vijayakumar T, Jayram J, Cheekireddy V, Himaja D, Teja Y, Narayanasamy D . Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review. Curr Ther Res Clin Exp. 2017; 84:4-9. PMC: 5522976. DOI: 10.1016/j.curtheres.2017.01.005. View

11.

Moses R, Round E, Shentu Y, Golm G, ONeill E, Gantz I . A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2015; 8(5):701-11. DOI: 10.1111/1753-0407.12351. View

12.

Raccah D, Huet D, Dib A, Joseph F, Landers B, Escalada J . Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabet Med. 2017; 34(9):1193-1204. PMC: 5599968. DOI: 10.1111/dme.13390. View

13.

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

14.

Pai L, Li T, Hwu Y, Chang S, Chen L, Chang P . The effectiveness of regular leisure-time physical activities on long-term glycemic control in people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2016; 113:77-85. DOI: 10.1016/j.diabres.2016.01.011. View

15.

Home P, Pocock S, Beck-Nielsen H, Curtis P, Gomis R, Hanefeld M . Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373(9681):2125-35. DOI: 10.1016/S0140-6736(09)60953-3. View

16.

Erpeldinger S, Rehman M, Berkhout C, Pigache C, Zerbib Y, Regnault F . Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. BMC Endocr Disord. 2016; 16(1):39. PMC: 4939045. DOI: 10.1186/s12902-016-0120-z. View

17.

Li L, Li S, Deng K, Liu J, Vandvik P, Zhao P . Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016; 352:i610. PMC: 4772781. DOI: 10.1136/bmj.i610. View

18.

Breslin M, Mullan R, Montori V . The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008; 73(3):465-72. DOI: 10.1016/j.pec.2008.07.024. View

19.

Htike Z, Zaccardi F, Papamargaritis D, Webb D, Khunti K, Davies M . Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2016; 19(4):524-536. DOI: 10.1111/dom.12849. View

20.

Hanefeld M, Brunetti P, Schernthaner G, Matthews D, Charbonnel B . One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2003; 27(1):141-7. DOI: 10.2337/diacare.27.1.141. View